Before enrolling, verify the clinician, medication and form, dose-price schedule, pharmacy or manufacturer channel, cash due today, renewal amount, annual commitment, and cancellation rules
Nat Med 2: 1254-1258, 1996
Familiar Failures: The 1990s and 2000s After Fen-Phen, the industry tried new approaches, with mixed results
In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
Known side effects (class effects similar to other GLP-1 medications) Gastrointestinal issues (very common): Nausea: 38-43% of participants vs 11% placebo Diarrhea: 33-35% vs 13% placebo Vomiting: 20-21% vs 0% placebo Constipation: 22-25% vs 9% placebo Decreased appetite: 18-19% vs 9% placebo These are expected with incretin-based therapies and typically improve over time as your body adjusts
People using insulin or sulfonylureas should discuss potential dose adjustments with their healthcare provider when planning to consume alcohol and should consider keeping glucagon available if prescribed